10 results on '"Gutiérrez-Cobos A"'
Search Results
2. Evaluation of two RT-PCR techniques for SARS-CoV-2 RNA detection in serum for microbiological diagnosis
- Author
-
Martín Ramírez, Alexandra, Zurita Cruz, Nelly Daniela, Gutiérrez-Cobos, Ainhoa, Rodríguez Serrano, Diego Aníbal, González Álvaro, Isidoro, Roy Vallejo, Emilia, Gómez de Frutos, Sara, Fontán García-Rodrigo, Leticia, and Cardeñoso Domingo, Laura
- Published
- 2022
- Full Text
- View/download PDF
3. Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies
- Author
-
Gutiérrez-Cobos, Ainhoa, Gómez de Frutos, Sara, Domingo García, Diego, Navarro Lara, Eva, Yarci Carrión, Ayla, Fontán García-Rodrigo, Leticia, Fraile Torres, Arturo Manuel, and Cardeñoso Domingo, Laura
- Published
- 2021
- Full Text
- View/download PDF
4. SARS-CoV-2 Viremia Precedes an IL6 Response in Severe COVID-19 Patients: Results of a Longitudinal Prospective Cohort
- Author
-
Emilia Roy-Vallejo, Laura Cardeñoso, Ana Triguero-Martínez, Marta Chicot Llano, Nelly Zurita, Elena Ávalos, Ana Barrios, Julia Hernando, Javier Ortiz, Sebastián C. Rodríguez-García, Marianela Ciudad Sañudo, Celeste Marcos, Elena García Castillo, Leticia Fontán García-Rodrigo, Begoña González, Rosa Méndez, Isabel Iturrate, Ancor Sanz-García, Almudena Villa, Ana Sánchez-Azofra, Begoña Quicios, David Arribas, Jesús Álvarez Rodríguez, Pablo Patiño, Marina Trigueros, Miren Uriarte, Alexandra Martín-Ramírez, Cristina Arévalo Román, José María Galván-Román, Rosario García-Vicuña, Julio Ancochea, Cecilia Muñoz-Calleja, Elena Fernández-Ruiz, Rafael de la Cámara, Carmen Suárez Fernández, Isidoro González-Álvaro, Diego A. Rodríguez-Serrano, the PREDINMUN-COVID Group, Jesús Sanz, Pedro Casado, Ángela Gutiérrez, Azucena Bautista, Pilar Hernández, Nuria Ruiz Giménez, Berta Moyano, Paloma Gil, María Jesús Delgado, Pedro Parra, Beatriz Sánchez, Carmen Sáez, Marta Fernández Rico, Diego Domingo García, Teresa Alarcón Cavero, María Auxiliadora Semiglia Chong, Ainhoa Gutiérrez Cobos, Santos Castañeda, Irene Llorente, Eva G. Tomero, Noelia García Castañeda, Nuria Montes, Cristina Dominguez Peña, David Jiménez Jiménez, Pablo Villamayor, Alfonso Canabal, Tamara Alonso, Carolina Cisneros, Claudia Valenzuela, Francisco Javier García Pérez, Rosa María Girón, Javier Aspa, M. del Perpetuo Socorro Churruca, Enrique Zamora, Adrián Martínez, Mar Barrio Mayo, Rosalina Henares Espi, Francisco Sánchez-Madrid, Enrique Martín Gayo, Ildefonso Sánchez-Cerrillo, Ana Marcos Jimenez, Pedro Martínez-Fleta, Celia López-Sanz, Ligia Gabrie, Luciana del Campo Guerola, Reyes Tejedor, and Rosa Carracedo Rodríguez
- Subjects
SARS-CoV-2 ,viremia ,interleukin 6 (IL-6) ,prognosis ,COVID-19 ,Medicine (General) ,R5-920 - Abstract
BackgroundInterleukin 6 (IL6) levels and SARS-CoV-2 viremia have been correlated with COVID-19 severity. The association over time between them has not been assessed in a prospective cohort. Our aim was to evaluate the relationship between SARS-CoV-2 viremia and time evolution of IL6 levels in a COVID-19 prospective cohort.MethodsSecondary analysis from a prospective cohort including COVID-19 hospitalized patients from Hospital Universitario La Princesa between November 2020 and January 2021. Serial plasma samples were collected from admission until discharge. Viral load was quantified by Real-Time Polymerase Chain Reaction and IL6 levels with an enzyme immunoassay. To represent the evolution over time of both variables we used the graphic command twoway of Stata.ResultsA total of 57 patients were recruited, with median age of 63 years (IQR [53–81]), 61.4% male and 68.4% Caucasian. The peak of viremia appeared shortly after symptom onset in patients with persistent viremia (more than 1 sample with > 1.3 log10 copies/ml) and also in those with at least one IL6 > 30 pg/ml, followed by a progressive increase in IL6 around 10 days later. Persistent viremia in the first week of hospitalization was associated with higher levels of IL6. Both IL6 and SARS-CoV-2 viral load were higher in males, with a quicker increase with age.ConclusionIn those patients with worse outcomes, an early peak of SARS-CoV-2 viral load precedes an increase in IL6 levels. Monitoring SARS-CoV-2 viral load during the first week after symptom onset may be helpful to predict disease severity in COVID-19 patients.
- Published
- 2022
- Full Text
- View/download PDF
5. Effect of a SARS-CoV-2 booster vaccine dose on the immune response of adults with Down syndrome
- Author
-
Yarci-Carrión, Ayla, Esparcia-Pinedo, Laura, Mateo-Jiménez, Gloria, Alfranca, Arantzazu, Real de Asúa, Diego, and Gutiérrez-Cobos, Ainhoa
- Published
- 2023
- Full Text
- View/download PDF
6. Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies
- Author
-
Sara Gómez de Frutos, Arturo Manuel Fraile Torres, Laura Cardeñoso Domingo, Leticia Fontán García-Rodrigo, Eva Navarro Lara, Ainhoa Gutiérrez-Cobos, Ayla Yarci Carrión, and Diego Domingo García
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,030106 microbiology ,Antibodies, Viral ,Diagnostic accuracy ,Sensitivity and Specificity ,law.invention ,Serology ,COVID-19 Serological Testing ,03 medical and health sciences ,0302 clinical medicine ,Medical microbiology ,law ,medicine ,Humans ,030212 general & internal medicine ,Polymerase chain reaction ,Chemiluminescence ,Aged ,Immunoassay ,biology ,business.industry ,SARS-CoV-2 ,Respiratory infection ,COVID-19 ,General Medicine ,Gold standard (test) ,Middle Aged ,Virology ,Reverse transcriptase ,Immunoglobulin Isotypes ,Infectious Diseases ,COVID-19 Nucleic Acid Testing ,biology.protein ,Original Article ,Antibody assays ,Female ,Antibody ,business - Abstract
Antibody detection is essential to establish exposure, infection, and immunity to SARS-CoV-2, as well as to perform epidemiological studies. The worldwide urge for new diagnostic tools to control the pandemic has led to a quick incorporation in clinical practice of the recently developed serological assays. However, as only few comparative studies have been published, there is a lack of data about the diagnostic accuracy of currently available assays. We evaluated the diagnostic accuracy to detect Ig G, Ig M+A, and/or IgA anti SARS-CoV-2 of 10 different assays: lateral flow card immunoassays, 4 enzyme-linked immunosorbent assay (ELISA), and 3 chemiluminescent particle immunoassays (CMIA). Using reverse transcriptase polymerase chain reaction (RT-PCR) for COVID-19 as gold standard, sensitivity, specificity, PPV, and NPV were determined. Each assay was tested in 2 groups, namely, positive control, formed by 50 sera from 50 patients with SARS-CoV-2 pneumonia with positive RT-PCR; and negative control, formed by 50 sera from 50 patients with respiratory infection non-COVID-19. Sensitivity range of the 10 assays evaluated for patients with positive COVID-19 RT-PCR was 40-77% (65-81% considering IgG plus IgM). Specificity ranged 83-100%. VPP and VPN were respectively 81-100% and 61.6-81%. Among the lateral flow immunoassays, the highest sensitivity and specificity results were found in Wondfo® SARS-CoV-2 Antibody Test. ELISA IgG and IgA from EUROIMMUN® were the most sensitive ELISA. However, poor results were obtained for isolated detection of IgG. We found similar sensitivity for IgG with SARS-CoV-2 for Architect by Abbott® and ELISA by Vircell®. Results obtained varied widely among the assays evaluated. Due to a better specificity, overall diagnostic accuracy of the assays evaluated was higher in case of positive result. On the other side, lack of antibody detection should be taken with care because of the low sensitivity described. Highest diagnostic accuracy was obtained with ELISA and CMIAs, but they last much longer.
- Published
- 2020
7. Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination.
- Author
-
Esparcia-Pinedo, Laura, Yarci-Carrión, Ayla, Mateo-Jiménez, Gloria, Ropero, Noelia, Gómez-Cabañas, Laura, Lancho-Sánchez, Ángel, Almendro-Vázquez, Patricia, Martín-Gayo, Enrique, Paz-Artal, Estela, Sanchez-Madrid, Francisco, Moldenhauer, Fernando, Gutiérrez-Cobos, Ainhoa, Asúa, Diego Real de, and Alfranca, Arantzazu
- Subjects
COVID-19 ,IMMUNIZATION ,DOWN syndrome ,COVID-19 vaccines ,IMMUNE system ,ANTIBODY formation ,DESCRIPTIVE statistics ,DATA analysis software ,PHENOTYPES - Abstract
Background Immune dysregulation in individuals with Down syndrome (DS) leads to an increased risk for hospitalization and death due to coronavirus disease 2019 (COVID-19) and may impair the generation of protective immunity after vaccine administration. Methods The cellular and humoral responses of 55 individuals with DS who received a complete SARS-CoV-2 vaccination regime at 1 to 3 (visit [V 1]) and 6 (V2) months were characterized. Results SARS-CoV-2–reactive CD4+ and CD8+ T lymphocytes with a predominant Th1 phenotype were observed at V1 and increased at V2. Likewise, an increase in SARS-CoV-2–specific circulating Tfh (cTfh) cells and CD8+ CXCR5+ PD-1hi lymphocytes was already observed at V1 after vaccine administration. Specific immunoglobulin G (IgG) antibodies against SARS-CoV-2 S protein were detected in 96% and 98% of subjects at V1 and V2, respectively, although IgG titers decreased significantly between both time points. Conclusions Our findings show that DS individuals develop an effective immune response to usual regimes of SARS-CoV-2 vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study
- Author
-
José María Galván-Román, Sebastián C. Rodríguez-García, Emilia Roy-Vallejo, Ana Marcos-Jiménez, Santiago Sánchez-Alonso, Carlos Fernández-Díaz, Ana Alcaraz-Serna, Tamara Mateu-Albero, Pablo Rodríguez-Cortes, Ildefonso Sánchez-Cerrillo, Laura Esparcia, Pedro Martínez-Fleta, Celia López-Sanz, Ligia Gabrie, Luciana del Campo Guerola, Carmen Suárez-Fernández, Julio Ancochea, Alfonso Canabal, Patricia Albert, Diego A. Rodríguez-Serrano, Juan Mariano Aguilar, Carmen del Arco, Ignacio de los Santos, Lucio García-Fraile, Rafael de la Cámara, José María Serra, Esther Ramírez, Tamara Alonso, Pedro Landete, Joan B. Soriano, Enrique Martín-Gayo, Arturo Fraile Torres, Nelly Daniela Zurita Cruz, Rosario García-Vicuña, Laura Cardeñoso, Francisco Sánchez-Madrid, Arantzazu Alfranca, Cecilia Muñoz-Calleja, Isidoro González-Álvaro, Teresa Alvarado, Pablo Martínez, Francisco Javier de la Cuerda Llorente, Natalia Villalba, Mónica Negro, Elvira Contreras, Ana del Rey, Cristina Santiago, Manuel Junquera, Raquel Caminero, Francisco Javier Val, Sonia González, Marta Caño, Isabel López, Andrés von Wernitz, Bárbara Retana, Iñigo Guerra, Jorge Sorando, Lydia Chao, María José Cárdenas, Verónica Espiga, Pablo Chicharro, Pedro Rodríguez, Iñigo Hernando Alday, Miguel Sampedro, Jorge Prada, Eukene Rojo Aldama, Yolanda Real, María Caldas, Sergio Casabona, Aitor Lanas-Gimeno, Rafael de la Camara, Angela Figuera Alvárez, Beatriz Aguadol, Alberto Morell, Amparo Ibáñez Zurriaga, María Pérez Abanades, Silvia Ruiz García, Tomás Gallego Aranda, María Ruiz, Concepción Martínez Nieto, Javier Aspa, Elena Fernández, Ma José Calzada, Reyes Tejedor, Judit Iglesias, Fernando Suarez, Juan Antonio Sánchez, Beatriz Abad, Carmen Suarez, Emilia Roy, Jesus Sanz, Eduardo Sanchez, Fernando Moldenhauer, Pedro Casado, Jose Curbelo, Angela Gutierrez, Azucena Bautista, Nuria Ruiz Giménez, Angelica Fernandez, Pedro Parra, Berta Moyano, Ana Barrios, Diego Real de Asua, Beatriz Sanchez, Carmen Saez, Marianela Ciudad, Desiré Navas, Laura Cardeñoso Domingo, María del Carmen Cuevas Torresano, Diego Domingo García, Teresa Alarcón Cavero, Alicia García Blanco, Alexandra Martín Ramírez, María Auxiliadora Semiglia Chong, Ainhoa Gutiérrez Cobos, Arturo Manuel Fraile Torres, Carmen Sanchez-Gonzalez, Antonio Fernádez Perpén, Carolina Díaz Pérez, Joan Soriano, Carolina Cisneros, Elena García Castillo, Francisco Javier García Pérez, Rosa María Girón, Celeste Marcos, Enrique Zamora, Patricia García García, Santos Castañeda, Sebastián Rodríguez-García, Irene Llorente Cubas, Eva G. Tomero, Noelia García Castañeda, Ana Ma Ortiz, Cristina Valero, Miren Uriarte, and Nuria Montes
- Subjects
0301 basic medicine ,ARDS ,CAR, chimeric antigen receptor ,medicine.medical_treatment ,Invasive Mechanical Ventilation ,chemistry.chemical_compound ,0302 clinical medicine ,SatO2, mean oxygen saturation ,Interquartile range ,Fraction of inspired oxygen ,Immunology and Allergy ,030212 general & internal medicine ,COVID-19, coronavirus disease 2019 ,PaO2/FiO2, arterial oxygen tension/fraction of inspired oxygen ratio ,TNF, tumor necrosis factor ,AUC, Area under curve ,AEMPS, Spanish Agency for Drugs and Health Devices ,Tocilizumab ,CRS, cytokine release syndrome ,PCT, procalcitonin ,Cytokine release syndrome ,CRP, C-reactive protein ,LR, negative likelihood ratio ,medicine.medical_specialty ,Immunology ,LR+, positive likelihood ratio ,Article ,03 medical and health sciences ,Internal medicine ,medicine ,TCZ, Tocilizumab ,Survival rate ,ARDS, acute respiratory distress syndrome ,IQR, interquartile range ,Mechanical ventilation ,business.industry ,Interleukin-6 ,COVID-19 ,Odds ratio ,PaO2, arterial oxygen tension ,medicine.disease ,IL, interleukin ,ROC, receiver operating characteristic ,030104 developmental biology ,IMV, invasive mechanical ventilation ,chemistry ,COPD, chronic obstructive pulmonary disease ,STROBE, Strengthening the Reporting of Observational Studies in Epidemiology ,business ,SD, standard deviation - Abstract
Background COVID-19 patients can develop a cytokine release syndrome that eventually leads to acute respiratory distress syndrome (ARDS) requiring invasive mechanical ventilation (IMV). Since interleukin-6 (IL-6) is a relevant cytokine in ARDS, the blockade of its receptor with Tocilizumab (TCZ) could reduce mortality and/or morbidity in severe COVID-19. Objective To determine whether baseline IL-6 serum levels can predict the need for IMV and the response to TCZ. Methods Retrospective observational study performed in hospitalized patients diagnosed of COVID-19. Clinical information and laboratory findings, including IL-6 levels, were collected approximately 3 and 9 days after admission to be matched with pre- and post-administration of TCZ. Multivariable logistic and linear regressions, and survival analysis were performed depending on outcomes: need for IMV, evolution of arterial oxygen tension/fraction of inspired oxygen ratio (PaO2/FiO2) or mortality. Results One hundred and forty-six patients were studied, predominantly male (66%); median age was 63 years. Forty-four patients (30%) required IMV, and 58 patients (40%) received treatment with TCZ. IL-6 levels>30 pg/ml was the best predictor for IMV (OR:7.1; p30 pg/ml predicts IMV requirement in patients with COVID-19 and contributes to establish an adequate indication for TCZ administration., Baseline IL-6 serum levels>30 pg/ml identify severe COVID-19 patients and should be used to guide the intervention with IL-6R inhibitors, aiming to improve their use in an uncertain and evolving therapeutic scenario.
- Published
- 2020
9. Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis.
- Author
-
Roy-Vallejo E, Fernández De Córdoba-Oñate S, Delgado-Wicke P, Triguero-Martínez A, Montes N, Carracedo-Rodríguez R, Zurita-Cruz N, Marcos-Jiménez A, Lamana A, Galván-Román JM, Villapalos García G, Zubiaur P, Ciudad M, Rabes L, Sanz M, Rodríguez C, Villa A, Rodríguez JÁ, Marcos C, Hernando J, Díaz-Fernández P, Abad F, de Los Santos I, Rodríguez Serrano DA, García-Vicuña R, Suárez Fernández C, P Gomariz R, Muñoz-Calleja C, Fernández-Ruiz E, González-Álvaro I, Cardeñoso L, Barrios A, Sanz J, Casado P, Gutiérrez Á, Bautista A, Hernández P, Ruiz Giménez N, Moyano B, Gil P, Jesús Delgado M, Parra P, Sánchez B, Sáez C, Fernández Rico M, Arévalo Román C, Castañeda S, Llorente I, G Tomero E, García Castañeda N, Uriarte M, Fontán García-Rodrigo L, Domingo García D, Alarcón Cavero T, Auxiliadora Semiglia Chong M, Gutiérrez Cobos A, Sánchez-Madrid F, Martín Gayo E, Sánchez-Cerrillo I, Martínez-Fleta P, López-Sanz C, Gabrie L, Del Campo Guerola L, Tejedor R, Ancochea J, García Castillo E, Ávalos E, Sánchez-Azofra A, Alonso T, Cisneros C, Valenzuela C, Javier García Pérez F, María Girón R, Aspa J, Marcos C, Del Perpetuo Socorro Churruca M, Zamora E, Martínez A, Barrio Mayo M, Henares Espi R, Méndez R, Arribas D, Chicot Llano M, González B, Quicios B, Patiño P, Trigueros M, Dominguez Peña C, Jiménez Jiménez D, Villamayor P, Canabal A, de la Cámara R, Ortiz J, and Iturrate I
- Abstract
Introduction: SARS-CoV-2 viral load has been related to COVID-19 severity. The main aim of this study was to evaluate the relationship between SARS-CoV-2 viremia and SNPs in genes previously studied by our group as predictors of COVID-19 severity., Materials and Methods: Retrospective observational study including 340 patients hospitalized for COVID-19 in the University Hospital La Princesa between March 2020 and December 2021, with at least one viremia determination. Positive viremia was considered when viral load was above the quantifiable threshold (20 copies/ml). A total of 38 SNPs were genotyped. To study their association with viremia a multivariate logistic regression was performed., Results: The mean age of the studied population was 64.5 years (SD 16.6), 60.9% patients were male and 79.4% white non-Hispanic. Only 126 patients (37.1%) had at least one positive viremia. After adjustment by confounders, the presence of the minor alleles of rs2071746 ( HMOX1 ; T/T genotype OR 9.9 p < 0.0001), rs78958998 (probably associated with SERPING1 expression; A/T genotype OR 2.3, p = 0.04 and T/T genotype OR 12.9, p < 0.0001), and rs713400 (eQTL for TMPRSS2 ; C/T + T/T genotype OR 1.86, p = 0.10) were associated with higher risk of viremia, whereas the minor alleles of rs11052877 ( CD69 ; A/G genotype OR 0.5, p = 0.04 and G/G genotype OR 0.3, p = 0.01), rs2660 ( OAS1 ; A/G genotype OR 0.6, p = 0.08), rs896 ( VIPR1 ; T/T genotype OR 0.4, p = 0.02) and rs33980500 ( TRAF3IP2 ; C/T + T/T genotype OR 0.3, p = 0.01) were associated with lower risk of viremia., Conclusion: Genetic variants in HMOX1 (rs2071746), SERPING1 (rs78958998), TMPRSS2 (rs713400), CD69 (rs11052877), TRAF3IP2 (rs33980500), OAS1 (rs2660) and VIPR1 (rs896) could explain heterogeneity in SARS-CoV-2 viremia in our population., Competing Interests: FA, has been consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, FAES, Farmalíder, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva and Zambon. IG-Á reports grants from Instituto de Salud Carlos III, during the course of the study; personal fees from Lilly and Sanofi; personal fees and non-financial support from BMS; personal fees and non-financial support from Abbvie; research support, personal fees and non-financial support from Roche Laboratories; research support from Gebro Pharma; non-financial support from MSD, Pfizer and Novartis, not related to the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Roy-Vallejo, Fernández de Córdoba-Oñate, Delgado-Wicke, Triguero-Martínez, Montes, Carracedo-Rodríguez, Zurita-Cruz, Marcos-Jiménez, Lamana, Galván-Román, Villapalos García, Zubiaur, Ciudad, Rabes, Sanz, Rodríguez, Villa, Rodríguez, Marcos, Hernando, Díaz-Fernández, Abad, de los Santos, Rodríguez Serrano, García-Vicuña, Suárez Fernández, P. Gomariz, Muñoz-Calleja, Fernández-Ruiz, González-Álvaro Cardeñoso and the PREDINMUN-COVID Group.)
- Published
- 2023
- Full Text
- View/download PDF
10. Healing of chronic hepatitis delta relapsing to pegylated interferon with tenofovir.
- Author
-
Ezquerra-Durán A, Gutiérrez-Cobos A, and García-Buey L
- Subjects
- Drug Therapy, Combination, Hepatitis, Chronic drug therapy, Humans, Polyethylene Glycols adverse effects, Recombinant Proteins therapeutic use, Tenofovir therapeutic use, Treatment Outcome, Antiviral Agents adverse effects, Interferon-alpha adverse effects
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.